Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faming Zhang

Showing results (181-190 of 189) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 189 results.
Journal of Gastroenterology and Hepatology|March 27, 2025
Preferred Reporting Items for Microbiotherapy (PRIM) Guidelines Across Medical Disciplines: An International Delphi ConsensusFaming Zhang, Michael A Kamm, Xia Wu, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluationCarlos Jaramillo, J Eugenio de Diego, Chafiq Hamdouchi, et al.
Oncotarget|February 23, 2018
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitorJonathan M Yingling, William T McMillen, Lei Yan, et al.
Gut|July 5, 2020
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemicGianluca Ianiro, Benjamin H Mullish, Colleen R Kelly, et al.
The Lancet. Gastroenterology & Hepatology|February 11, 2021
SARS-CoV-2 vaccines and donor recruitment for FMTGianluca Ianiro, Benjamin H Mullish, Christian Lodberg Hvas, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
Imeta|October 20, 2025
Shaping the future of probiotics, live biotherapeutic products, and fecal microbiota transplantation: 30 scientific recommendations from the CHINAGUT ConferenceWeihong Wang, Nan Bu, Hailong Cao, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2024
International consensus statement on microbiome testing in clinical practiceSerena Porcari, Benjamin H Mullish, Francesco Asnicar, et al.
Hepatology International|June 15, 2024
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver diseaseHuai Zhang, Giovanni Targher, Christopher D Byrne, et al.
Pageof 19

Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
Journal of Gastroenterology and Hepatology|March 27, 2025
Preferred Reporting Items for Microbiotherapy (PRIM) Guidelines Across Medical Disciplines: An International Delphi ConsensusFaming Zhang, Michael A Kamm, Xia Wu, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluationCarlos Jaramillo, J Eugenio de Diego, Chafiq Hamdouchi, et al.
Oncotarget|February 23, 2018
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitorJonathan M Yingling, William T McMillen, Lei Yan, et al.
Gut|July 5, 2020
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemicGianluca Ianiro, Benjamin H Mullish, Colleen R Kelly, et al.
The Lancet. Gastroenterology & Hepatology|February 11, 2021
SARS-CoV-2 vaccines and donor recruitment for FMTGianluca Ianiro, Benjamin H Mullish, Christian Lodberg Hvas, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
Imeta|October 20, 2025
Shaping the future of probiotics, live biotherapeutic products, and fecal microbiota transplantation: 30 scientific recommendations from the CHINAGUT ConferenceWeihong Wang, Nan Bu, Hailong Cao, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2024
International consensus statement on microbiome testing in clinical practiceSerena Porcari, Benjamin H Mullish, Francesco Asnicar, et al.
Hepatology International|June 15, 2024
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver diseaseHuai Zhang, Giovanni Targher, Christopher D Byrne, et al.
Pageof 19